Treatment of Renal Fibrosis-Turning Challenges into Opportunities

Area of Science:

• Nephrology
• Pharmacology
• Translational Medicine

Background:

• Chronic kidney disease (CKD) is a progressive condition with limited effective treatments.
• Renal fibrosis is a common pathological hallmark of CKD, making it a key therapeutic target.
• Preclinical studies have identified numerous antifibrotic molecular pathways, some with drugs in clinical development.

Purpose of the Study:

• To review current clinical trials of antifibrotic agents in CKD patients.
• To focus on drugs with direct antifibrotic effects, including pirfenidone and neutralizing antibodies.
• To explore reasons for the limited translation of antifibrotic therapies into clinical practice for renal fibrosis.

Main Methods:

• Literature review of clinical trials involving antifibrotic drugs for CKD.
• Focus on agents targeting profibrotic growth factors and cell connection proteins.
• Analysis of challenges in clinical translation and potential future strategies.

Main Results:

• Few clinical trials are currently investigating antifibrotic drugs in CKD patients.
• Pirfenidone and neutralizing antibodies are among the agents being studied.
• Significant gaps exist between preclinical findings and clinical application for renal fibrosis treatment.

Conclusions:

• There is a critical need to improve the translation of antifibrotic therapies for CKD.
• Future strategies should include optimized patient selection, companion diagnostics, sensitive biomarkers, and advanced drug-targeting approaches.
• Enhanced clinical trial designs are essential for effective treatment of renal fibrosis in CKD.